具有上市公司多年投融资管理经验，拥有丰富的行业人脉和项目资源，具有较强的综合系统能力和执行力。累计完成10亿元的债券发行，50亿元的银行融资，对资本市场有着深刻的认识
项目需求点击详情
潘育新先生是朗然资本的创始合伙人。他熟悉大型综合超市、超级市场、便利店、药妆店等各业态的投资、发展、采购、运营、财务等多方面业务，并拥有超过十五年的股权与创业投资管理经历，在企业并购重组和公司全面运营管理方面有着丰富的经验。他曾在联华超市股份有限公司担任高管职位，分管投资工作，主导和参与近20项并购重组项目，并领导快客便利和联华复星药业取得了富有成效的业绩。此外，潘育新先生还是德式Board Game行业的权威人士，创立和投资了两家企业。 潘育新先生拥有哈尔滨工业大学管理学硕士学位，并在2013年获得美国亚利桑那州立大学工商管理硕士学位和上海国家会计学院财务总监资格培训证书。
项目需求点击详情
姜涛女士是朗然资本的创始合伙人。她在医疗领域不同业态工作近二十年，对中国医疗健康行业状态及发展有深刻的认知与见地。她曾在知名三甲医院承担科室管理工作，对医院运营及民众医疗需求了解非常深入。她曾在飞利浦家庭医疗保健部担任销售及市场总监，对医药销售管理、渠道建立及市场营销均有丰富的实际经验。她曾在医疗创投企业担任CEO和董事，熟悉科技企业从初建到运作的实践过程。她曾担任多家风投机构医疗行业高级咨询顾问，对业内资本运作方式及投资方向有清晰的观点与认识。 姜涛女士拥有中国医科大学临床医学专业学士学位，取得中科院心理所人力资源管理硕士学历，具有主治医师资质。
项目需求点击详情
工商管理学硕士, 分子生物学硕士 作为济峰资本的创始合伙人之一，赵晋专注于医药、医疗器械、医疗诊断和动物医学领域的投资。在创立济峰资本之前，赵晋是维梧资本在中国第一位管理合伙人，曾主导或参与康辉医疗、景峰医药（SZ：0009008）、上海海利生物（SHA: 603718.SS）、长春长生、南京健友、上海斯迈康和海尔生物医疗等的投资。 赵晋在风险投资/成长期投资领域积累了19年以上的跨国工作经验，这赋予他在投资、运营、战略、商业拓展、销售/市场和执行布局等方面独到深刻的见解。
项目需求点击详情
工商管理学硕士, 药学学士 作为济峰资本的创始合伙人之一，余征坤专注于医疗设备、药品、医疗诊断和医疗服务/IT公司领域的投资。在创立济峰资本之前，作为著名投资机构IDG资本的合伙人，余征坤曾主导过多个重大投资项目。在中国市场余征坤具备丰富的工作经验，他曾先后负责过新华信咨询的顾问工作和江中药业（已在中国上市）的销售工作。他负责的投资项目主要有康辉医疗、中国生物制品有限公司（NASDAQ：CBPO）、九安医疗（SZ:002432）、双成药业（SZ:002693）、鹏爱医院、傲锐东源、瑞慈医疗、闻泰医疗、博恩登特和乐奥医疗等。 在中国医疗行业，余征坤具有丰富的战略和运营经验，并帮助多家医疗企业成功退市。他于2012年被清科集团评为“十大最佳风险投资者之一”，于2013年被《创业邦杂志》列入“40岁以下最成功的40位投资者之一”。 余征坤在江西中医药大学取得了药学学士学位，随后在长江商学院取得了MBA学位。
项目需求点击详情
首席财务官 作为济峰资本的首席财务官，许文懿全权负责上海办公室的所有财务工作。在加入济峰资本之前，许文懿曾担任金浦投资风控副总裁，主要负责财务尽职调查、风险控制、项目管理、财务等多方面工作，作为核心成员参与了40宗以上项目的尽调。此前，许先生先后在普华永道中天会计师事务所和申银万国投资有限公司工作，具有超过十年的审计及尽调经验，精通多个领域的财务知识，包括IPO、上市公司和非上市公司、内部控制等，并在高科技行业（医疗/TMT）和传统消费制造业具有丰富经验。 许文懿毕业于复旦大学并持有注册会计师证。
项目需求点击详情
工商管理硕士，生物医学学士 作为济峰资本硅谷办公室国际业务团队的重要成员，何耀立同时担任业务总监一职。在加入济峰资本之前，何耀立曾担任扬子江药业集团（中国最大的民办制药企业之一）的业务拓展经理。作为扬子江药业集团旧金山团队的重要成员，何耀立主要负责为市值数十亿美元的母公司寻找潜在的美国 、欧洲和日本等国际合作伙伴，并对这些潜在伙伴进行评估、尽职调查和商务谈判。何耀立曾先后在多家医疗诊断、纳米科技和数字健康领域的创业公司里担任过研发工程师，还担任过其他公司的创始成员。 何耀立出生于加利福尼亚成长于硅谷，借地势之便手握丰富的创业公司资源。在意识到中国将发展成为全球主要经济力量后，他坚持不懈地学习普通话，并选择专注于他所擅长的医疗领域。 何耀立在欧文加州大学开展了生物光子和微流体领域的专业研究，并成功取得生物医学学士学位，随后还取得了清华大学和麻省理工学院联合培养项目的MBA学位。
项目需求点击详情
Dr. Min Cui is the Founder and Managing Director of Decheng Capital. At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies in China and US. He is currently a board member of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, GRAIL (observer), Hummingbird Bioscience, Ketai Medical, Levitas, and SINOMED. His investment portfolio also includes 3SBio (HK Stock Exchange: 1530), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Epizyme (NASDAQ: EPZM), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), and Ion Torrent Systems (acquired by Life Technologies). Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm in San Francisco. At Bay City, he led investment opportunities in US as well as all its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America.
项目需求点击详情
Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception. At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED. Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999. Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.
项目需求点击详情
Dr. Qiang Xu is a Principal at Decheng Capital and has been with the firm since its inception. He is currently serving on the boards of BCFoods and GYT HealthCare Services. He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
项目需求点击详情
Dr. Nick Pliam is a Principal at Decheng Capital. He has been with the firm since its inception and Bay City Capital since 2005. Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories). He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.
项目需求点击详情
Dr. Tony Tong is a Vice President of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of CardiMED and Insight Lifetech. Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.
项目需求点击详情
微信公众号
